The Life Sciences team advised Zafgen, Inc. (Nasdaq:ZFGN) on its definitive merger agreement with Chondrial Therapeutics, Inc. Under the agreement, Chondrial will become a wholly-owned subsidiary of Zafgen and the stockholders of Chondrial Therapeutics will become the majority owners of Zafgen’s outstanding common stock upon the close of the merger. The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.
Zafgen is a biopharmaceutical company that has leveraged its proprietary MetAP2 biology platform to pioneer the study of MetAP2 inhibitors in both common and rare metabolic disorders. Chondrial Therapeutics is a clinical-stage biotechnology company focused on the treatment of complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. The merger is expected to provide significant resources to advance CTI-1601 and expand efforts on the development of additional potential treatments for other rare diseases.
The Goodwin team was led by partners Andrew Goodman, Danielle Lauzon and Mitchell Bloom.
For more details, read the press release and an article in Xconomy.